key: cord-0847116-utd3r209
authors: McDonald, Emily G; Lee, Todd C
title: Nirmatrelvir-ritonavir for COVID-19
date: 2022-02-14
journal: CMAJ
DOI: 10.1503/cmaj.220081
sha: 825a3f62e1789cf93b8455b81035b2c622108de5
doc_id: 847116
cord_uid: utd3r209

nan

Particular attention should be paid to high-risk medications: antiarrhythmics (amiodarone, digoxin), oral antithrombotics (apixaban, rivaroxaban, ticagrelor), statins (atorvastatin, lovastatin, simvastatin), benzodiazepines (diazepam), opioids (methadone, fentanyl), anticonvulsants, neuropsychiatric drugs and immunosuppressants (Appendix 1, available at www.cmaj.ca/lookup/doi/10.1503/ cmaj.220081/tab-related-content).

Strategies should be implemented during and 3-5 days after treatment. 5 Some medications (Appendix 1) reduce the efficacy of nirmatrelvirritonavir and could lead to treatment failure or virologic resistance, 1 and alternative treatments for COVID-19 should be considered. 4 Pharmacist consultation is recommended in many instances (Appendix 1). Practice | Five things to know about ...

Emily G. McDonald MD MSc, Todd C. Lee 

Bethesda (MD): National Institutes of Health

Product monograph including patient medication information: Paxlovid. Kirkland (QC): Pfizer Canada ULC

Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death

Outpatient therapies for COVID-19: How do we choose? Open Forum Infect Dis

Fact sheet for healthcare providers: emergency use authorization for Paxlovid

Competing interests: Emily McDonald reports receiving salary support from the Fonds de Recherche Santé-Québec, and operating funds from the Canadian Institutes of Health Research (CIHR). Dr. McDonald also holds copyright in the software MedSafer. Todd Lee reports receiving research salary support from the Fonds de Recherche Santé-Québec, and operating funds from CIHR and the Interdisciplinary Initiative in Infection and Immunity (MI4). Dr. Lee also holds copyright in the software MedSafer. This article has been peer reviewed.